We are a multinational biopharmaceutical company developing new treatments for unmet medical needs, in particular cancer, by harnessing and unleashing the power of the immune system.
Galileo utilizes cutting-edge science to develop therapeutic monoclonal antibodies and antibody-drug conjugates to provide solutions for patients suffering from diseases for which there are currently no satisfactory treatments.
Our company’s paradigm-shifting approach to science holds unique promise to change the status quo for the development and use of targeted immunotherapies to fight diseases more successfully than ever before.
Lead the industry in the discovery and development of innovative, antibody-based therapies to treat the consequences of devastating diseases for patients, families and caregivers.
We strive to discover and develop innovative biotherapies in order to transform the lives of patients who suffer from unmet medical needs.
